AstraZeneca at ATS 2017


At AstraZeneca, we aim to transform the treatment of respiratory disease with our growing portfolio of inhaled and biologics medicines along with scientific research targeting disease modification and early intervention. We are excited to join clinicians, researchers and scientists at the 2017 American Thoracic Society (ATS) Annual Meeting to discuss the latest advancements in respiratory science.

Follow us on Twitter for the latest updates from AstraZeneca at #ATS2017.

Understanding severe asthma and its burden


Severe asthma heterogeneity


Understanding severe and uncontrolled asthma


OCS co-morbidity






Respiratory at AstraZeneca and MedImmune




What we're working on

We are innovating to target specific biologic treatments to patient types, so that we might optimise individual responses to treatment.


New approaches in the treatment of asthma

Targeting the immune system to try and restore the balance in asthma patients

Read the full story

Veeva ID: Z4-4722

Date of next review: May 2018